Thresholds

Threshold Bio is a clinical-stage biotechnology company dedicated to developing hypoxia-activated prodrugs (HAPs) for the treatment of cancer. The company's technology platform targets the hypoxic regions of solid tumors, which are typically resistant to conventional chemotherapy and radiation. Its lead candidate, evofosfamide (TH-302), is designed to be selectively activated in low-oxygen environments, releasing a potent DNA-alkylating agent directly within the tumor microenvironment. Threshold Bio aims to revitalize the HAP field by leveraging advanced patient selection biomarkers and combination strategies. The company is also advancing tarloxotinib, a hypoxia-activated EGFR/HER2 inhibitor, for patients with specific genetic mutations.